Citations (86)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
X. Li, X. Ruan, M. Gu & A. O. Mueck. (2019) PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol. Climacteric 22:5, pages 483-488.
Read now
Read now
Mark A Moyad & Mark C Scholz. (2014) Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. Research and Reports in Urology 6, pages 71-77.
Read now
Read now
D. P. McDonnell, C.-Y. Chang & E. R. Nelson. (2014) The estrogen receptor as a mediator of the pathological actions of cholesterol in breast cancer. Climacteric 17:sup2, pages 60-65.
Read now
Read now
Victor G Vogel. (2011) Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer: Targets and Therapy 3, pages 127-137.
Read now
Read now
Alvin Eisner & Shiuh-Wen Luoh. (2011) Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease. Current Eye Research 36:10, pages 867-885.
Read now
Read now
V. Ziller, K. Wetzel, I. Kyvernitakis, B. Seker-Pektas & P. Hadji. (2011) Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene. Climacteric 14:2, pages 228-235.
Read now
Read now
Zeynep Madak-Erdogan, Mathieu Lupien, Fabio Stossi, Myles Brown & Benita S. Katzenellenbogen. (2011) Genomic Collaboration of Estrogen Receptor α and Extracellular Signal-Regulated Kinase 2 in Regulating Gene and Proliferation Programs. Molecular and Cellular Biology 31:1, pages 226-236.
Read now
Read now
Articles from other publishers (79)
Sandip Narayan Wagh & Vivekanand Arvind Chatpalliwar. (2023) Design, Docking, In silico ADME Prediction of Novel 2-substituted-5-
hydroxy-1-(1-methyl-3-morpholinopropyl)-1H-indole-3-carboxamide Derivatives
for Estrogen Receptor Alfa in AF-2 Domain for Effective Anticancer
Treatment. Letters in Drug Design & Discovery 20:8, pages 1066-1085.
Crossref
Crossref
Shujun Huang, Pingzhao Hu & Ted M. Lakowski. (2022) Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer. The Pharmacogenomics Journal 23:4, pages 61-72.
Crossref
Crossref
Erika L. Spaeth, Gillian S. Dite, John L. Hopper & Richard Allman. (2023) Validation of an Abridged Breast Cancer Risk Prediction Model for the General Population. Cancer Prevention Research 16:5, pages 281-291.
Crossref
Crossref
Aditi Sharma, Lalit Sharma, Shouvik Kumar Nandy, Nazrana Payal, Shivam Yadav, Celia Vargas-De-La-Cruz, Md. Khalid Anwer, Haroon Khan, Tapan Behl & Simona Gabriela Bungau. (2023) Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer. Molecules 28:2, pages 750.
Crossref
Crossref
Anthanasios Sevdalis, Xiaoyan Deng, Dipankar Bandyopadhyay & Kandace P. McGuire. (2022) The Value of Tyrer-Cuzick Versus Gail Risk Modeling in Predicting Benefit from Screening MRI in Breast Cancer. European Journal of Breast Health 18:1, pages 79-84.
Crossref
Crossref
Paul Hernandez, Ciaran O’Brien, Seth J. Concors, Zhonglin Wang, Guanghui Ge, Wayne W. Hancock & Matthew H. Levine. (2022) The Selective Estrogen Receptor Modulator, Raloxifene, Is Protective Against Renal Ischemia–reperfusion Injury. Transplantation 106:11, pages 2166-2171.
Crossref
Crossref
Ritihaas Surya Challapalli, Roisin M. Dwyer, Niall McInerney, Michael J. Kerin & Aoife J. Lowery. (2022) Evaluation of human adipose-derived stromal cell behaviour following exposure to Tamoxifen. Tissue and Cell 77, pages 101858.
Crossref
Crossref
Lauren E. Hipp, Bailey B. Hulswit & Kara J. Milliron. (2022) Clinical tools and counseling considerations for breast cancer risk assessment and evaluation for hereditary cancer risk. Best Practice & Research Clinical Obstetrics & Gynaecology 82, pages 12-29.
Crossref
Crossref
Daniela Iaconis, Licia Bordi, Giulia Matusali, Carmine Talarico, Candida Manelfi, Maria Candida Cesta, Mara Zippoli, Francesca Caccuri, Antonella Bugatti, Alberto Zani, Federica Filippini, Laura Scorzolini, Marco Gobbi, Marten Beeg, Arianna Piotti, Monica Montopoli, Veronica Cocetta, Silvia Bressan, Enrico M. Bucci, Arnaldo Caruso, Emanuele Nicastri, Marcello Allegretti & Andrea R. Beccari. (2022) Characterization of raloxifene as a potential pharmacological agent against SARS-CoV-2 and its variants. Cell Death & Disease 13:5.
Crossref
Crossref
Zhenkun Fu, Zhoujun Lin, Mao Yang & Chenggang Li. (2022) Cardiac Toxicity From Adjuvant Targeting Treatment for Breast Cancer Post-Surgery. Frontiers in Oncology 12.
Crossref
Crossref
Sara G. Manore, Daniel L. Doheny, Grace L. Wong & Hui-Wen Lo. (2022) IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment. Frontiers in Oncology 12.
Crossref
Crossref
Marcello Allegretti, Maria Candida Cesta, Mara Zippoli, Andrea Beccari, Carmine Talarico, Flavio Mantelli, Enrico M. Bucci, Laura Scorzolini & Emanuele Nicastri. (2021) Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell Death & Differentiation 29:1, pages 156-166.
Crossref
Crossref
Fahmida Rasha, Monica Sharma & Kevin Pruitt. (2021) Mechanisms of endocrine therapy resistance in breast cancer. Molecular and Cellular Endocrinology 532, pages 111322.
Crossref
Crossref
Chenxi Zhao, Chu Tang, Changhao Li, Wentao Ning, Zhiye Hu, Lilan Xin, Hai-Bing Zhou & Jian Huang. (2021) Novel hybrid conjugates with dual estrogen receptor α degradation and histone deacetylase inhibitory activities for breast cancer therapy. Bioorganic & Medicinal Chemistry 40, pages 116185.
Crossref
Crossref
Katherine B. D'Antonio, Meaghan McGuire & Karlyn Rupert. (2021) Managing patients with high-risk breast lesions, precursors on the breast neoplasia pathway. JAAPA 34:5, pages 35-39.
Crossref
Crossref
Andrea Lucia Bastos Carneiro, Ana Paula Curi Spadella, Fabiola Amaral de Souza, Karen Borelli Ferreira Alves, Joaquim Teodoro de Araujo-Neto, Mauro Abi Haidar & Rita de Cássia de Maio Dardes. (2021) Effects of Raloxifene Combined with Low-dose Conjugated Estrogen on the Endometrium in Menopausal Women at High Risk for Breast Cancer. Clinics 76, pages e2380.
Crossref
Crossref
Dogan S. Polat, Jennifer G. Schopp, Firouzeh Arjmandi, Jessica Porembka, Venetia Sarode, Deborah Farr, Yin Xi & Basak E. Dogan. (2020) Performance of a clinical and imaging-based multivariate model as decision support tool to help save unnecessary surgeries for high-risk breast lesions. Breast Cancer Research and Treatment 185:2, pages 479-494.
Crossref
Crossref
Brittany L. Murphy, Kelly K. Hunt & Sarah M. DeSnyder. 2021. Breast & Gynecological Diseases. Breast & Gynecological Diseases
137
156
.
Richard R. Love, Michael Baum, Susan M. Love & Andrea M. Straus. (2020) Clinical practice to address tamoxifen nonadherence. Breast Cancer Research and Treatment 184:3, pages 675-682.
Crossref
Crossref
Altaf Mohammed, Jennifer T Fox & Mark Steven Miller. (2019) Cancer Chemoprevention: Preclinical In Vivo Alternate Dosing Strategies to Reduce Drug Toxicities. Toxicological Sciences 170:2, pages 251-259.
Crossref
Crossref
Gillian Kuehner, Jeanne Darbinian, Laurel Habel, Karen Axelsson, Sherry Butler, Sharon Chang, Rhona Chen & Lou Fehrenbacher. (2019) Benign Papillary Breast Mass Lesions: Favorable Outcomes with Surgical Excision or Imaging Surveillance. Annals of Surgical Oncology 26:6, pages 1695-1703.
Crossref
Crossref
Holli A. Loomans-Kropp & Asad Umar. (2019) Cancer prevention and screening: the next step in the era of precision medicine. npj Precision Oncology 3:1.
Crossref
Crossref
F.F. Guilherme, H.R. Bottura & D.A. Raia. (2018) RELAÇÃO ENTRE O DESENVOLVIMENTO DE CATARATA NOS PACIENTES EM USO DE TAMOXIFENO. RELAÇÃO ENTRE O DESENVOLVIMENTO DE CATARATA NOS PACIENTES EM USO DE TAMOXIFENO.
J. A. Bennett, W. Mansouri, Q. Lin, P. Feustel & T. T. Andersen. (2017) Pharmacodynamic and Pharmacokinetic Properties of AFPep, a Novel Peptide for the Treatment of Breast Cancer. International Journal of Peptide Research and Therapeutics 24:3, pages 431-439.
Crossref
Crossref
Anthony Howell, Michelle N. Harvie, Sacha J. Howell, Louise S. Donnelly & D. Gareth Evans. 2018. Cancer Prevention and Screening. Cancer Prevention and Screening
111
128
.
Helen Krontiras, Meagan Farmer & Julie Whatley. (2018) Breast Cancer Genetics and Indications for Prophylactic Mastectomy. Surgical Clinics of North America 98:4, pages 677-685.
Crossref
Crossref
Hitisha K. Patel & Teeru Bihani. (2018) Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics 186, pages 1-24.
Crossref
Crossref
Stuart G. Baker. (2017) Simple Decision-Analytic Functions of the AUC for Ruling Out a Risk Prediction Model and an Added Predictor. Medical Decision Making 38:2, pages 225-234.
Crossref
Crossref
Marcia M. Marques, Adriane F. Evangelista, Taciane Macedo, René Aloisio da Costa Vieira, Cristovam Scapulatempo-Neto, Rui M. Reis, André L. Carvalho & Ismael Dale Cotrim Guerreiro da Silva. (2018) Expression of tumor suppressors miR-195 and let-7a as potential biomarkers of invasive breast cancer. Clinics 73, pages e184.
Crossref
Crossref
Jinny Gunn, E. Alexa Elder & Sarah McLaughlin. 2018. Atypical Breast Proliferative Lesions and Benign Breast Disease. Atypical Breast Proliferative Lesions and Benign Breast Disease
129
145
.
Michael Co, Rosemarie Chiu, Tung Milly Chiu, Yau Chun Chong, Swan Lau, Yung Ho Lee, Hoi Man To & Ava Kwong. (2017) Nipple-Sparing Mastectomy and Its Application on BRCA Gene Mutation Carrier. Clinical Breast Cancer 17:8, pages 581-584.
Crossref
Crossref
Martina Lichtenfels, Arethuza da Silva Dornelles, Fernanda dos Santos Petry, Martina Blank, Caroline Brunetto de Farias, Rafael Roesler & Gilberto Schwartsmann. (2017) The anticancer estrogen receptor antagonist tamoxifen impairs consolidation of inhibitory avoidance memory through estrogen receptor alpha. Journal of Neural Transmission 124:11, pages 1331-1339.
Crossref
Crossref
R.J. Watters, R.J. Hartmaier, H.U. Osmanbeyoglu, R.M. Gillihan, J.M. Rae, L. Liao, K. Chen, W. Li, X. Lu & S. Oesterreich. (2017) Steroid receptor coactivator-1 can regulate osteoblastogenesis independently of estrogen. Molecular and Cellular Endocrinology 448, pages 21-27.
Crossref
Crossref
Abul Kalam, Sushama Talegaonkar & Divya Vohora. (2017) Effects of raloxifene against letrozole-induced bone loss in chemically-induced model of menopause in mice. Molecular and Cellular Endocrinology 440, pages 34-43.
Crossref
Crossref
Ayong Cao, Liang Huang & Zhimin Shao. 2017. Translational Research in Breast Cancer. Translational Research in Breast Cancer
41
57
.
B. Zeidan, K. Anderson, L. Peiris, D. Rainsbury & S. Laws. (2016) The impact of tamoxifen brand switch on side effects and patient compliance in hormone receptor positive breast cancer patients. The Breast 29, pages 62-67.
Crossref
Crossref
Talar Tatarian, Claire Sokas, Miguel Rufail, Melissa Lazar, Sanchi Malhotra, Juan P. Palazzo, Elizabeth Hsu, Theodore Tsangaris & Adam C. Berger. (2016) Intraductal Papilloma with Benign Pathology on Breast Core Biopsy: To Excise or Not?. Annals of Surgical Oncology 23:8, pages 2501-2507.
Crossref
Crossref
P. Butow & K.A. Phillips. (2016) Medication to reduce breast cancer risk: why is uptake low?. Annals of Oncology 27:4, pages 553-554.
Crossref
Crossref
Freya R. Schnabel, Sarah Pivo, Jennifer Chun, Shira Schwartz, Ana Paula Refinetti, Deborah Axelrod & Amber Guth. (2016) Breast Cancer Profile among Patients with a History of Chemoprevention. International Journal of Breast Cancer 2016, pages 1-5.
Crossref
Crossref
Lida A. Mina, Anna Maria Storniolo, Hal Douglas Kipfer, Cindy Hunter & Kandice K. LudwigSheila Mamandur Hiler, Alain Mina & Lida A. Mina. 2016. Breast Cancer Prevention and Treatment. Breast Cancer Prevention and Treatment
5
11
.
Myrto Ashe. 2015. Integrative Therapies for Depression. Integrative Therapies for Depression
251
262
.
Patricia A. Mackey & Michael D. Whitaker. (2015) Osteoporosis: A Therapeutic Update. The Journal for Nurse Practitioners 11:10, pages 1011-1017.
Crossref
Crossref
Jacinta Abraham & John Staffurth. 2015. Practical Clinical Oncology. Practical Clinical Oncology
24
41
.
Sven O. Skouby, Kaijie Pan, John R. Thompson, Barry S. Komm & Sebastian Mirkin. (2015) Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables. Menopause 22:6, pages 640-649.
Crossref
Crossref
Lewis K. Penny & Heather M. Wallace. (2015) The challenges for cancer chemoprevention. Chem. Soc. Rev. 44:24, pages 8836-8847.
Crossref
Crossref
Chad L. Deal & Abby G. Abelson. 2015. Rheumatology. Rheumatology
1663
1673
.
Eric R. Schuur & James P. DeAndrade. 2015. International Manual of Oncology Practice. International Manual of Oncology Practice
155
200
.
Alfonso M. Pluchinotta, Gianni Saguatti & Daniela Zuccarello. 2015. The Outpatient Breast Clinic. The Outpatient Breast Clinic
31
59
.
Georg F. WeberGeorg F. Weber. 2015. Molecular Therapies of Cancer. Molecular Therapies of Cancer
303
332
.
Suzanne E. Wardell, Erik R. Nelson & Donald P. McDonnell. (2014) From empirical to mechanism-based discovery of clinically useful Selective Estrogen Receptor Modulators (SERMs). Steroids 90, pages 30-38.
Crossref
Crossref
Ava Kwong, Annie Tsz-Wai Chu, Christine Teen-Sum Wu & Desiree Man-Sik Tse. (2014) Attitudes and compliance of clinical management after genetic testing for hereditary breast and ovarian cancer among high-risk Southern Chinese females with breast cancer history. Familial Cancer 13:3, pages 423-430.
Crossref
Crossref
Spencer Keene, Charles Azuelos & Shyamal K. Majumdar. (2014) Sensitivity Evaluation of Two Human Breast Cancer Cell Lines to Tamoxifen through Apoptosis Induction. Open Journal of Apoptosis 03:04, pages 70-77.
Crossref
Crossref
D. Gareth R. Evans, Ava Kwong & Andrew D. Baildam. 2014. Breast Surgery. Breast Surgery
127
145
.
Naveena B. Janakiram, Altaf Mohammed, Yuting Zhang, Misty Brewer, Taylor Bryant, Stan Lightfoot, Vernon E. Steele & Chinthalapally V. Rao. (2013) Chemopreventive Efficacy of Raloxifene, Bexarotene, and Their Combination on the Progression of Chemically Induced Colon Adenomas to Adenocarcinomas in Rats. Cancer Prevention Research 6:12, pages 1251-1261.
Crossref
Crossref
Daniel E Abbott & Jason B FlemingRosalinda Alvarado. 2013. Complex General Surgical Oncology: A Case-Based Approach - Volume 1. Complex General Surgical Oncology: A Case-Based Approach - Volume 1
64
74
.
Santiago Palacios, Tobie J. de Villiers, Fiorenzo De Cicco Nardone, Amy B. Levine, Robert Williams, Teresa Hines, Sebastian Mirkin & Arkadi A. Chines. (2013) Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 76:1, pages 81-87.
Crossref
Crossref
Beth DuPree. 2013. Lifestyle Medicine, Second Edition. Lifestyle Medicine, Second Edition
287
297
.
Leena Hilakivi-Clarke, Sonia de Assis & Anni Warri. (2013) Exposures to Synthetic Estrogens at Different Times During the Life, and Their Effect on Breast Cancer Risk. Journal of Mammary Gland Biology and Neoplasia 18:1, pages 25-42.
Crossref
Crossref
Olivier M. Dorchies, Julie Reutenauer-Patte, Elyes Dahmane, Hesham M. Ismail, Olivier Petermann, Ophélie Patthey-Vuadens, Sophie A. Comyn, Elinam Gayi, Tony Piacenza, Robert J. Handa, Laurent A. Décosterd & Urs T. Ruegg. (2013) The Anticancer Drug Tamoxifen Counteracts the Pathology in a Mouse Model of Duchenne Muscular Dystrophy. The American Journal of Pathology 182:2, pages 485-504.
Crossref
Crossref
Suzanne E. Wardell, Dmitri Kazmin & Donald P. McDonnell. (2012) Research Resource: Transcriptional Profiling in a Cellular Model of Breast Cancer Reveals Functional and Mechanistic Differences Between Clinically Relevant SERM and Between SERM/Estrogen Complexes. Molecular Endocrinology 26:7, pages 1235-1248.
Crossref
Crossref
Colin McCowan & Alastair M Thompson. (2012) The importance of nonpharmacogenetic factors in endocrine therapy. Pharmacogenomics 13:6, pages 721-728.
Crossref
Crossref
Chunyu Wang & Powel H. Brown. 2012. Genetically Engineered Mice for Cancer Research. Genetically Engineered Mice for Cancer Research
497
526
.
Crystal Blake, Kimberly M Fabick, Kenneth DR Setchell, Trent D Lund & Edwin D Lephart. (2011) Neuromodulation by soy diets or equol: Anti-depressive & anti-obesity-like influences, age- & hormone-dependent effects. BMC Neuroscience 12:1.
Crossref
Crossref
Fritcher Emily G. Barr, Amy C. Degnim, Lynn C. Hartmann, Derek C. Radisky, Judy C. Boughey, Stephanie S. Anderson, Robert A. Vierkant, Marlene H. Frost, Daniel W. Visscher & Carol Reynolds. (2011) Estrogen Receptor Expression in Atypical Hyperplasia: Lack of Association with Breast Cancer. Cancer Prevention Research 4:3, pages 435-444.
Crossref
Crossref
Xue DAI & Jie WU. (2011) Selective Estrogen Receptor Modulator: Raloxifene. Journal of Reproduction and Contraception 22:1, pages 51-60.
Crossref
Crossref
Virginia Espina & Lance A. Liotta. (2010) What is the malignant nature of human ductal carcinoma in situ?. Nature Reviews Cancer 11:1, pages 68-75.
Crossref
Crossref
Paul TR Thiruchelvam, William E. Svensson & John Lynn. 2011. Gynaecology. Gynaecology
707
749
.
Chad L. Deal & Abby G. Abelson. 2011. Rheumatology. Rheumatology
1975
1988.e4
.
Stephen D. Hursting, Laura M. Lashinger, Powel H. Brown & Susan N. Perkins. 2011. Tumor Models in Cancer Research. Tumor Models in Cancer Research
423
443
.
Deborah Fenlon & Kay Townsend. 2010. Breast Cancer Nursing Care and Management. Breast Cancer Nursing Care and Management
190
214
.
Masa-Aki Shibata, Junji Morimoto, Eiko Shibata, Hitomi Kurose, Kanako Akamatsu, Zhong-Lian Li, Moriaki Kusakabe, Masahide Ohmichi & Yoshinori Otsuki. (2010) Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer. BMC Cancer 10:1.
Crossref
Crossref
E. Dean. (2010) Un cas de cataracte bilatérale suspecté d’être lié à l’utilisation de tamoxifène chez un chien. Pratique Médicale et Chirurgicale de l'Animal de Compagnie 45:3, pages 107-117.
Crossref
Crossref
Ava Kwong, Connie H. N. Wong, Catherine Shea, Dacita T. K. Suen & Catherine L. Y. Choi. (2010) Choice of Management of Southern Chinese BRCA Mutation Carriers. World Journal of Surgery 34:7, pages 1416-1426.
Crossref
Crossref
Chad D. Moore, Christopher A. Reilly & Garold S. Yost. (2010) CYP3A4-Mediated Oxygenation versus Dehydrogenation of Raloxifene. Biochemistry 49:21, pages 4466-4475.
Crossref
Crossref
Jacqueline RamírezMark J RatainFederico Innocenti. (2010) Uridine 5´-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncology 6:4, pages 563-585.
Crossref
Crossref
Sumi Dinda, Amelita Sanchez & Virinder K. Moudgil. (2010) Effects of LY117018 (a SERM analog of raloxifene) on tumor suppressor proteins and proliferation of breast cancer cells. Hormone Molecular Biology and Clinical Investigation 2:1.
Crossref
Crossref
Carolyn D. DuSell, Erik R. Nelson, Bryan M. Wittmann, Jackie A. Fretz, Dmitri Kazmin, Russell S. Thomas, J. Wesley Pike & Donald P. McDonnell. (2010) Regulation of Aryl Hydrocarbon Receptor Function by Selective Estrogen Receptor Modulators. Molecular Endocrinology 24:1, pages 33-46.
Crossref
Crossref
Frank L. MeyskensJr.Jr.. (2009) Food Extracts for Chemoprevention: Quo Vadis?. Cancer Prevention Research 2:7, pages 608-610.
Crossref
Crossref
Mindy Goldman & Kim O'Hair. (2009) Women's Health, Breast Health. Obstetrical & Gynecological Survey 64:7, pages 469-480.
Crossref
Crossref